Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Spiriva (tiotropium bromide) inhalation capsules

Study type: Observational

Funder types: Industry

Identifiers

NCT02177318

205.314

Details and patient eligibility

About

To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings

Enrollment: 3,588 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with COPD

Exclusion criteria

-There is no exclusion criterion, because this post marketing study (PMS) is observational survey under condition of normal clinical practice

Trial design

3,588 participants in 1 patient group

Patients with COPD

Treatment:

Drug: Spiriva (tiotropium bromide) inhalation capsules